You are here

PCSK9 inhibitors

Merck bets big on oral PCSK9 inhibitor, putting 6-year outcome study at heart of phase 3 program

Merck bets big on oral PCSK9 inhibitor, putting 6-year outcome study at heart of phase 3 program

Fierce Biotech

PCSK9 inhibitors

clinical trials

cardiovascular disease

Flag link:

Cholesterol-focused Esperion loses appetite for oral PCSK9 collab with Serometrix

Cholesterol-focused Esperion loses appetite for oral PCSK9 collab with Serometrix

Fierce Biotech

Esperion Therapeutics

PCSK9 inhibitors

Flag link:

Junshi's lipid lowering drug hits phase 3 goals, teeing up challenge to Amgen, Sanofi in growth market

Junshi's lipid lowering drug hits phase 3 goals, teeing up challenge to Amgen, Sanofi in growth market

Fierce Biotech

Junshi Biosciences

clinical trials

PCSK9 inhibitors

Flag link:

PCSK9 pipeline shows signs of saturation

PCSK9 pipeline shows signs of saturation

EP Vantage

Ionis Pharmaceuticals

PCSK9 inhibitors

Flag link:

Can A New Cholesterol Drug Restore Merck’s Prominence In Heart Drugs?

Can A New Cholesterol Drug Restore Merck’s Prominence In Heart Drugs?

Forbes

PCSK9 inhibitors

Flag link:

Merck’s Anti-Cholesterol Drug Threatens Esperion, Other PCSK9 Inhibitor Makers

Merck’s Anti-Cholesterol Drug Threatens Esperion, Other PCSK9 Inhibitor Makers

BioSpace

PCSK9 inhibitors

Flag link:

Merck looks to ditch the needles with its next-gen oral PCSK9 inhibitor for high cholesterol

Merck looks to ditch the needles with its next-gen oral PCSK9 inhibitor for high cholesterol

Endpoints

oral PCSK9 inhibitors

PCSK9 inhibitors

Flag link:

Amgen dealt another blow in closely watched PCSK9 patent case against Sanofi, Regeneron

Amgen dealt another blow in closely watched PCSK9 patent case against Sanofi, Regeneron

Fierce Pharma

PCSK9 inhibitors

Flag link:

AZ buys oral PCSK9 cholesterol drug from Dogma Therapeutics

AZ buys oral PCSK9 cholesterol drug from Dogma Therapeutics

Pharmaforum

Dogma Therapeutics

PCSK9 inhibitors

Flag link:

ACC: New owner Novartis presents pooled inclisiran data cutting LDL cholesterol by half

ACC: New owner Novartis presents pooled inclisiran data cutting LDL cholesterol by half

Fierce Biotech

PCSK9 inhibitors

Flag link:

MedCo's PCSK9 challenger steals the show at ESC with winning data

MedCo's PCSK9 challenger steals the show at ESC with winning data

Fierce Pharma

Medicines Company

PCSK9 inhibitors

European Society of Cardiology

Flag link:

Sanofi, Regeneron score win against Amgen patents on PCSK9 med Repatha

Sanofi, Regeneron score win against Amgen patents on PCSK9 med Repatha

Fierce Pharma

PCSK9 inhibitors

Flag link:

Lackluster Amgen, Sanofi PCSK9 drugs could be under major threat from a new rival: analyst

Lackluster Amgen, Sanofi PCSK9 drugs could be under major threat from a new rival: analyst

Fierce Pharma

Medicines Company

PCSK9 inhibitors

Flag link:

New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)

New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)

Xconomy

PCSK9 inhibitors

Medicines Company

Flag link:

Will The Introduction Of A Third Potent Cholesterol Lowering Drug Expand or Shrink The Market?

Will The Introduction Of A Third Potent Cholesterol Lowering Drug Expand or Shrink The Market?

Forbes

The Medicines Company

PCSK9 inhibitors

Flag link:

Regeneron, Sanofi cut PCSK9 list price, matching earlier move by rival Amgen

Regeneron, Sanofi cut PCSK9 list price, matching earlier move by rival Amgen

Biopharma Dive

PCSK9 inhibitors

Flag link:

New drug options, risk factors added to US heart guidelines

New drug options, risk factors added to US heart guidelines

Reuters

PCSK9 inhibitors

Flag link:

Citing appeals court 'anarchy,' Amgen asks SCOTUS to weigh its PCSK9 patent spat with Sanofi

Citing appeals court 'anarchy,' Amgen asks SCOTUS to weigh its PCSK9 patent spat with Sanofi

Fierce Pharma

PCSK9 inhibitors

Flag link:

Are These Disappointing Drugs Back on Track to Billions?

Are These Disappointing Drugs Back on Track to Billions?

Motley Fool

PCSK9 inhibitors

Flag link:

PCSK9s appear to be meeting less payer resistance

PCSK9s appear to be meeting less payer resistance

Biopharma Dive

PCSK9 inhibitors

Flag link:

Pages